Institution
Trinity College, Dublin
Education•Dublin, Dublin, Ireland•
About: Trinity College, Dublin is a education organization based out in Dublin, Dublin, Ireland. It is known for research contribution in the topics: Population & Context (language use). The organization has 20576 authors who have published 48296 publications receiving 1780313 citations.
Topics: Population, Context (language use), Irish, Health care, Mental health
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The first endogenous miRNA is identified that limits NLRP3 inflammatory capacity during myeloid cell development and also a viral miRNA that takes advantage of this, limiting inflammation for its own purposes.
Abstract: Although microRNA (miRNA) regulation of TLR signaling is well established, this has not yet been observed for NLR proteins or the inflammasomes they form. We have now validated a highly conserved miR-223 target site in the NLRP3 3′-untranslated region. miR-223 expression decreases as monocytes differentiate into macrophages, whereas NLRP3 protein increases during this time. However, overexpression of miR-223 prevents accumulation of NLRP3 protein and inhibits IL-1β production from the inflammasome. Virus inhibition of the inflammasome is an emerging theme, and we have also identified an EBV miRNA that can target the miR-223 binding site in the NLRP3 3′-untranslated region. Furthermore, this virus miRNA can be secreted from infected B cells via exosomes to inhibit the NLRP3 inflammasome in noninfected cells. Therefore, we have identified both the first endogenous miRNA that limits NLRP3 inflammatory capacity during myeloid cell development and also a viral miRNA that takes advantage of this, limiting inflammation for its own purposes.
373 citations
••
TL;DR: Could the BCG vaccine be used to bridge the gap until a specific COVID-19 vaccine is developed?
Abstract: Bacillus Calmette–Guerin (BCG) vaccination has been reported to decrease susceptibility to respiratory tract infections, an effect proposed to be mediated by the general long-term boosting of innate immune mechanisms, also termed trained immunity. Here, we discuss the non-specific beneficial effects of BCG against viral infections and whether this vaccine may afford protection to COVID-19. Could the BCG vaccine be used to bridge the gap until a specific COVID-19 vaccine is developed? Luke O’Neill and Mihai Netea discuss the science behind this approach.
372 citations
••
TL;DR: Cognitive training improved performance on measures of executive function, working memory, and composite measures of cognitive function and memory and subjective cognitive performance might be improved by training in group versus individual settings.
371 citations
••
Istituto Superiore di Sanità1, Trinity College, Dublin2, Autonomous University of Barcelona3, Semmelweis University4, University of Turin5, University of Palermo6, University of Porto7, University of Barcelona8, Karolinska Institutet9, University of Oxford10, Ghent University11, Bilkent University12, University of Ljubljana13, University of Nantes14, University of Belgrade15, University of Ioannina16, University of Applied Sciences and Arts Northwestern Switzerland FHNW17, University of Valencia18, ORT Braude College of Engineering19, Oslo University Hospital20, University of Freiburg21, National Research Council22, University of Zurich23, Centre national de la recherche scientifique24, Innsbruck Medical University25, University of Helsinki26, Autonomous University of Madrid27, University of Duisburg-Essen28
TL;DR: The high potential of nanosized EVs for both diagnostic and therapeutic areas of nanomedicine, as demonstrated by the European Network on Microvesicles and Exosomes in Health and Disease (ME-HAD), is demonstrated.
Abstract: Recent research has demonstrated that all body fluids assessed contain substantial amounts of vesicles that range in size from 30 to 1000 nm and that are surrounded by phospholipid membranes containing different membrane microdomains such as lipid rafts and caveolae. The most prominent representatives of these so-called extracellular vesicles (EVs) are nanosized exosomes (70-150 nm), which are derivatives of the endosomal system, and microvesicles (100-1000 nm), which are produced by outward budding of the plasma membrane. Nanosized EVs are released by almost all cell types and mediate targeted intercellular communication under physiological and pathophysiological conditions. Containing cell-type-specific signatures, EVs have been proposed as biomarkers in a variety of diseases. Furthermore, according to their physical functions, EVs of selected cell types have been used as therapeutic agents in immune therapy, vaccination trials, regenerative medicine, and drug delivery. Undoubtedly, the rapidly emerging field of basic and applied EV research will significantly influence the biomedicinal landscape in the future. In this Perspective, we, a network of European scientists from clinical, academic, and industry settings collaborating through the H2020 European Cooperation in Science and Technology (COST) program European Network on Microvesicles and Exosomes in Health and Disease (ME-HAD), demonstrate the high potential of nanosized EVs for both diagnostic and therapeutic (i.e., theranostic) areas of nanomedicine.
371 citations
••
TL;DR: This review provides state of the art of the nanotechnological applications for cancer therapy and advances a novel concept of personalized nanomedical theranostic therapy using iron oxide magnetic nanoparticles in conjunction with MRI imaging.
Abstract: In a report from 2008, The International Agency for Research on Cancer predicted a tripled cancer incidence from 1975, projecting a possible 13-17 million cancer deaths worldwide by 2030. While new treatments are evolving and reaching approval for different cancer types, the main prevention of cancer mortality is through early diagnosis, detection and treatment of malignant cell growth. The last decades have seen a development of new imaging techniques now in widespread clinical use. The development of nano-imaging through fluorescent imaging and magnetic resonance imaging (MRI) has the potential to detect and diagnose cancer at an earlier stage than with current imaging methods. The characteristic properties of nanoparticles result in their theranostic potential allowing for simultaneous detection of and treatment of the disease. This review provides state of the art of the nanotechnological applications for cancer therapy. Furthermore, it advances a novel concept of personalized nanomedical theranostic therapy using iron oxide magnetic nanoparticles in conjunction with MRI imaging. Regulatory and industrial perspectives are also included to outline future perspectives in nanotechnological cancer research.
370 citations
Authors
Showing all 20853 results
Name | H-index | Papers | Citations |
---|---|---|---|
Edward Giovannucci | 206 | 1671 | 179875 |
Robin M. Murray | 171 | 1539 | 116362 |
Mark E. Cooper | 158 | 1463 | 124887 |
Stephen J. O'Brien | 153 | 1062 | 93025 |
Amartya Sen | 149 | 689 | 141907 |
Kevin Murphy | 146 | 728 | 120475 |
Peter M. Visscher | 143 | 694 | 118115 |
Mihai G. Netea | 142 | 1170 | 86908 |
Kristine Yaffe | 136 | 794 | 72250 |
Cisca Wijmenga | 136 | 668 | 86572 |
David A. Jackson | 136 | 1095 | 68352 |
Patrick F. Sullivan | 133 | 594 | 92298 |
Thomas N. Williams | 132 | 1145 | 95109 |
Paul Brennan | 132 | 1221 | 72748 |
David Taylor | 131 | 2469 | 93220 |